Software & Services is the fastest-growing product type in the organ on chips market, compounding at 26.34% a year and taking share from the hardware lines that built the category.
Contrive Datum Insights has published "Organ On Chips Market Size, Share & Industry Analysis, By Product type (Instruments & Devices, Consumables (Chips & Reagents), Software & Services), Organ model (Liver-on-Chip, Lung-on-Chip, Kidney-on-Chip, Heart-on-Chip, Multi-Organ / Other Models), Application (Drug Discovery & Development, Toxicology & Safety Testing, Disease Modeling, Personalized Medicine & Other Applications), End user (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic & Government Research Institutes, Cosmetics & Other Industries), Technology (Single-Organ-on-Chip Systems, Multi-Organ (Body-on-Chip) Systems), and Regional Forecast, 2026-2034". The study sizes the global market at USD 105 million in 2025 and projects USD 132 million in 2026, rising to USD 718 million by 2034, a compound annual growth rate of 23.57%.
Why Software & Services Is Pulling Ahead
Organ-on-chip systems are microfluidic devices that recreate the structure and function of a human tissue on a small chip, so researchers can watch how living cells respond to a drug, chemical or disease condition. Each chip produces a stream of data that someone has to capture and interpret, and that is the work Software & Services does.
The study names the shift away from mandatory animal testing, including the FDA Modernization Act 2.0 and comparable reforms, as the largest single contributor to growth, with a high impact rating. As pharmaceutical and biotechnology sponsors build chip data into their safety packages, the analysis layer grows with them. Software & Services moves from 18% of revenue in 2025 to 22% by 2034, and from USD 18.9 million to USD 157.96 million.
Instruments & Devices, at 34% of 2025 revenue, grows at 20.91%, below the market's 23.57%. Several other lines outpace the market too. By end user, Cosmetics & Other Industries grows fastest at 30.45%, and by application, Personalized Medicine & Other Applications leads at 28.54%.
The bull case depends on regulators. If agencies accept organ-chip data across more indications and sponsors leave animal protocols sooner than current guidance implies, 2034 revenue reaches USD 811 million. If acceptance moves more slowly, 2034 revenue is held to USD 617 million.
Regions and the Larger Base
North America held 42% of global revenue in 2025, worth USD 44.1 million, and reaches USD 272.84 million by 2034. The United States is the largest single country at USD 39.69 million, or 37.8% of the global total. Asia Pacific climbs from 21% of revenue to 27%, with revenue rising from USD 22.05 million to USD 193.86 million. Middle East and Africa stays the smallest region at 3% in both years.
The largest product type is the slower story. Consumables (Chips & Reagents) accounts for 48% of 2025 revenue, USD 50.4 million, and still holds 50% in 2034. Yet no product type grows faster than Software & Services, so the biggest line trails the leader on pace even as it stays on top by size. Liver-on-Chip likewise led the organ model axis in 2025 with 30% of revenue, while Multi-Organ / Other Models grows fastest at 26.36%.
The study covers five axes and reports revenue and a growth rate for every line from 2020 to 2034, with bear, base and bull scenarios on the headline total. Country-level detail is given for all five regions, along with the competitive landscape and the research methodology. Delivered as a PDF; request a free sample to review it.